Final Survival Analysis of BELLINI: Venetoclax or Placebo Plus Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Source: 2021 American Society of Hematology Annual Meeting*
Download Slideset
December 11-14, 2021; Atlanta, Georgia
Venetoclax added to bortezomib/dexamethasone improved PFS in patients with relapsed/refractory multiple myeloma and t(11;14) but resulted in increased mortality in the overall patient population.
Format: Microsoft PowerPoint (.ppt)
File Size: 588 KB
Released: December 14, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Daiichi Sankyo, Inc.
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings